Drug Trial Radar · NCT01966029
BMN 110 Phase 3B in Australian Patients
Last checked: Nov 20, 2026Latest source record: Sep 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Jul 2013
Primary completion
Jul 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Oct 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is currently no treatment for MPS IVA other than supportive care for the clinical manifestations of the disease. Enzyme replacement therapy (ERT) with BMN 110 to replace the deficient GALNS is a potential new treatment option for MPS IVA patients. BMN 110, containing recombinant human GALNS (rhGALNS) developed by BioMarin is expected to reduce the progressive, pathologic accumulation of KS, and improve signs and symptoms of the disease. The objective of this Phase 3B open label study (110-502) will be to evaluate the safety and tolerability of 2.0 mg/kg/week (qw) of BMN 110 in Australian patients with MPS IVA. In addition, a number of secondary and tertiary efficacy endpoints will also be investigated. The dose and regimen of BMN 110 have been selected on the basis of data from a Phase 1/2 clinical study with BMN 110, nonclinical and in vitro studies with BMN 110, and clinical and nonclinical data from other enzyme replacement therapies. Extension Phase is included per amendment dated 10Mar 2014: To provide patients enrolled in the Initial Phase access to BMN 110 until commercial product becomes available in Australia and continue to assess long-term safety
Conditions
- Mucopolysaccharidosis IVA (Morquio A Syndrome)
Interventions
BMN 110Drug
All pateints receive treatment with BMN 110
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety AnalysisTime frame: The study period during which all non-serious AEs and SAEs will be reported begins after informed consent is obtained and through 30 days after the last study visit or 30 days after the last drug infusion, whichever comes first.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Pain and Anaesthesia Research Clinic, Royal Adelaide Hospital
Adelaide, Australia
Children's Hospital at Westmead
Westmead, New South Wales, Australia
Lady Cilento Children's Hospital (previous: Royal Children's Hospital)
Brisbane, Queensland, Australia
Murdoch Childrens Research Institute and Royal Children's Hospital
Melbourne, Victoria, Australia
Princess Margaret Hospital for Children
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.